Medtronic's attempt to strike Infuse lawsuit fails in court

Fri, 08/24/2012 - 2:07pm
Mass Device

Medtronic loses a motion for a summary judgment dismissing a lawsuit accusing the company of fraud and negligence in regard to its controversial Infuse bone growth protein.

Medtronic's Infuse bone growth protein

A lawsuit accusing Medtronic (NYSE:MDT) of fraud and negligence in promoting off-label use of its Infuse bone-growth protein creeps closer to trial following a California judge's decision to dismiss the medical device giant's request for dismissal.

The lawsuit, filed by a woman who received an Infuse bone graft procedure in her neck, claims Medtronic trained surgeons to use the product in an off-label manner and paid doctors millions of dollars to publish articles about off-label use.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.